Market Update (NYSE:MRK): Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs

[Business Wire] – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administration’s approval of BRAVECTO® for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose. Read more on this. , valued at $recting to http://finance.ya, ended trading yesterday at $. Looking at the equity, the company’s one day range is $ and has traded between $ over the past year. Priced at x this year’s forecasted earnings, MRK shares are relatively inexpensive compared to the industry’s x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $ which would be a $0.00 worse than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $0.00 . If realized, that would be a 0.00% decrease over the year-ago quarter. Recently, d MRK from to (/fi). Previously, d MRK from to . The average price target for MRK shares is $, which is 0.00% below where the stock opened this morning. See more in (NYSE:MRK) Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck, the American Diabetes Association and America’s Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic Market Update: Merck & Co Inc (NYSE:MRK) – Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review